Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W O'Connor

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 24, 2001
Reason for hope: the advent of disease-modifying therapies in multiple sclerosisP W O'Connor
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 3, 1999
IGIV in neurology--evidence and recommendationsV Bril, K Allenby, G Midroni, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Reducing clinical trial risk in multiple sclerosisC D De Gasperis-Brigante, J L Parker, P W O'Connor, et al.
Neurology|July 1, 1996
The effect of spectrum bias on the utility of magnetic resonance imaging and evoked potentials in the diagnosis of suspected multiple sclerosisP W O'Connor, C M Tansay, A S Detsky, et al.
International Journal of Clinical Practice|November 25, 2003
Pulmonary arteriovenous malformation: a rare, treatable cause of stroke in young adultsR R Retnakaran, M E Faughnan, R P Chan, et al.
The American Journal of the Medical Sciences|July 1, 1996
Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiencyD S Ng, P W O'Connor, C B Mortimer, et al.
Neurology|March 15, 2006
Ventricular enlargement in MS: one-year change at various stages of diseaseC M Dalton, K A Miszkiel, P W O'Connor, et al.
Neurology|March 29, 2007
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin, E M Frohman, B Hurwitz, et al.
Neurology|May 6, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisP W O'Connor, A Goodman, L Kappos, et al.
Neuroimage|June 5, 2007
Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesionJ T Chen, T Kuhlmann, G H Jansen, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 24, 2001
Reason for hope: the advent of disease-modifying therapies in multiple sclerosisP W O'Connor
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 3, 1999
IGIV in neurology--evidence and recommendationsV Bril, K Allenby, G Midroni, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Reducing clinical trial risk in multiple sclerosisC D De Gasperis-Brigante, J L Parker, P W O'Connor, et al.
Neurology|July 1, 1996
The effect of spectrum bias on the utility of magnetic resonance imaging and evoked potentials in the diagnosis of suspected multiple sclerosisP W O'Connor, C M Tansay, A S Detsky, et al.
International Journal of Clinical Practice|November 25, 2003
Pulmonary arteriovenous malformation: a rare, treatable cause of stroke in young adultsR R Retnakaran, M E Faughnan, R P Chan, et al.
The American Journal of the Medical Sciences|July 1, 1996
Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiencyD S Ng, P W O'Connor, C B Mortimer, et al.
Neurology|March 15, 2006
Ventricular enlargement in MS: one-year change at various stages of diseaseC M Dalton, K A Miszkiel, P W O'Connor, et al.
Neurology|March 29, 2007
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin, E M Frohman, B Hurwitz, et al.
Neurology|May 6, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisP W O'Connor, A Goodman, L Kappos, et al.
Neuroimage|June 5, 2007
Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesionJ T Chen, T Kuhlmann, G H Jansen, et al.
Pageof 3